Literature DB >> 32203601

Rapid Ketamine Infusion at an Analgesic Dose Resulting in Transient Hypotension and Bradycardia in the Emergency Department.

Alec D Emerling, Jason Fisher, Benjamin Walrath, Brendon Drew.   

Abstract

Ketamine's favorable hemodynamic and safety profile is motivating increasing use in the prehospital environment. Despite these advantages, certain side effects require advanced planning and training. We present a case of rapid intravenous administration of ketamine causing bradycardia and hypotension. A 46-year-old man presented to the emergency department for an exacerbation of chronic shoulder pain. Given the chronicity of the pain and multiple failed treatment attempts, ketamine at an analgesic dose was used. Despite the local protocol directing administration over several minutes, it was pushed rapidly, resulting in malaise, nausea, pallor, bradycardia, and hypotension. The patient returned to his baseline without intervention. This and other known side effects of ketamine, such as behavioral disturbances, altered sense of reality, and elevated heart rate and blood pressure, are well documented in the literature. With this report, the authors aim to raise awareness of transient bradycardia and hypotension associated with the rapid administration of ketamine at an analgesic dose. 2020.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32203601     DOI: 10.55460/N455-UKW4

Source DB:  PubMed          Journal:  J Spec Oper Med        ISSN: 1553-9768


  2 in total

1.  Effects of different dosages esketamine on cardiac conduction and heterogeneity of Cx43: the epicardial mapping in guinea pigs.

Authors:  Ying Cao; Yingnan Song; Zijun Wang; Jian Tang; Jing Yi; Yanqiu Liu; Li An; Zhijun Pan; Hong Gao
Journal:  Ann Transl Med       Date:  2022-07

2.  Human histamine H2 receptors can initiate cardiac arrhythmias in a transgenic mouse.

Authors:  U Gergs; J Weisgut; K Griethe; N Mißlinger; U Kirchhefer; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-06-24       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.